Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis
Study Details
Study Description
Brief Summary
Current medication treatments for KOA aim to relieve inflammation and pain, but they do little to delay or reverse the disease progression and most medications have obvious side effects. When the conservative treatments are useless to patients and joint deformities and joint disfunction, the patients may require surgery. Although surgery of the joints can relieve the pain temporarily, long-term effect (over 10 years) is hard to achieve.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Human adipose-derived mesenchymal progenitor cells (haMPCs) are obtained through a series of procedures: firstly, the fresh adipose tissue is digested with collagenase, filtered, centrifuged and then discard mature adipose cells to obtain adipose tissue-derived nuclear cells also called stromal vascular fraction cells (SVFs). In the end, haMPCs are prepared after being purified andamplified to P2-P5. When induced by specific factors, haMPCs have a potential for multilineage differentiation towards bone, cartilage and fat tissue both in vivo and in vitro. The haMPCs can secrete a number of soluble mediators to stimulate the proliferation of endogenous progenitor cells, to act as nutrients, to be immunosuppressive, to be anti-inflammatory, to prevent fibrosis and promote angiogenesis. The cytokines secreted by haMPCs play a synergic role in restoring the dynamic balance of synthesis and decompositon of cartilage tissue, and finally to repair the impaired cartilage.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mesenchymal progenitor cells Administrated for intra-articular use of Mesenchymal progenitor cells |
Biological: Mesenchymal progenitor cells
Administrated for intra-articular injection
|
| Active Comparator: Sodium Hyaluronate Administrated for intra-articular use of Sodium Hyaluronate. |
Biological: Sodium Hyaluronate
|
Outcome Measures
Primary Outcome Measures
- WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index) [12 months]
Secondary Outcome Measures
- Recording of Adverse Events and Serious Adverse Events [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The subject is between 18-70 years of age, regardless of gender
-
The subject has a Kellgren-Lawrence grading, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee, below grade 4
-
The subject or the subject's legally acceptable representative must be willing to participate in the trial, to receive cell therapy and to provide signed and dated informed consent forms
Exclusion Criteria:
-
The subject has an allergic history or is of an allergic constitution
-
The subject has uncontrolled or hard-to-control diseases of heart, liver, kidney or lung
-
The subject has uncontrolled or hard-to-control diseases of cardiovascular or endocrine system
-
The subject has severe infectious diseases or a malignant tumour
-
The subject has coagulation disorders
-
The subject has a BMI of over 30
-
The subject has used traditional Chinese medicine containing anti-inflammatory agents in the 2 weeks preceding the trial
-
The subject has received other intra-articular injections in the 2 months preceding the trial
-
The subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articular， Hemochromatosis，inflammatory arthropathy，avascular necrosis of femoral head，Paget's disease，hemophilic arthropathy，infectional arthritis，Charcot's disease，villonodular synovitis or synovial chondromatosis
-
The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases
-
The subject has a history of alcoholism, drug abuse, or mental illness
-
The subject has participated in any other clinical trial in the 3 months prior to this trial
-
The subject is pregnant, lactating or is planning to conceive within the next 6 months
-
The subject has any other unsuitable or adverse condition to be determined by the investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | General Hospital of Chinese Armed Police Force | Beijing | China | ||
| 2 | Shanghai Renji Hospital | Shanghai | China | 200127 |
Sponsors and Collaborators
- Cellular Biomedicine Group Ltd.
- RenJi Hospital
- General Hospital of Chinese Armed Police Force
Investigators
- Principal Investigator: Chunde Bao, MD, RenJi Hospital
- Principal Investigator: Zhongwen Zhang, MD, General Hospital of Chinese Armed Police Force
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CBMG-KOA-Ⅱb